DocGo, Inc. (DCGO)
0.2682
-0.01
(-4.89%)
USD |
NASDAQ |
Oct 16, 11:57
DocGo Research and Development Expense (Quarterly) : 3.446M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 3.446M |
| March 31, 2026 | 3.705M |
| December 31, 2025 | 3.773M |
| September 30, 2025 | 3.194M |
| June 30, 2025 | 2.957M |
| March 31, 2025 | 3.639M |
| December 31, 2024 | 3.686M |
| September 30, 2024 | 3.146M |
| June 30, 2024 | 2.369M |
| March 31, 2024 | 2.389M |
| December 31, 2023 | 3.186M |
| Date | Value |
|---|---|
| September 30, 2023 | 3.235M |
| June 30, 2023 | 2.574M |
| March 31, 2023 | 1.864M |
| December 31, 2022 | 1.722M |
| September 30, 2022 | 1.373M |
| June 30, 2022 | 1.148M |
| March 31, 2022 | 1.142M |
| September 30, 2021 | 0.8546M |
| June 30, 2021 | 0.6649M |
| March 31, 2021 | 0.5694M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Dogecoin Cash, Inc. | -- |
| Cryo-Cell International, Inc. | 0.0536M |
| Privia Health Group, Inc. | -- |
| Strata Critical Medical, Inc. | 1.006M |
| Syra Health Corp. | 0.0474M |